Rehmann Capital Advisory Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.48M Buy
11,708
+58
+0.5% +$7.64K 0.07% 202
2026
Q1
$1.62M Buy
11,650
+356
+3% +$49.9K 0.08% 169
2025
Q4
$1.39M Buy
11,294
+853
+8% +$104K 0.07% 185
2025
Q3
$1.16M Buy
+10,441
New +$1.19M 0.06% 205
2025
Q2
Sell
-10,073
Closed -$1.13M 629
2025
Q1
$1.13M Buy
10,073
+81
+0.8% +$8.36K 0.07% 205
2024
Q4
$923K Buy
9,992
+366
+4% +$33K 0.06% 229
2024
Q3
$807K Buy
9,626
+333
+4% +$25.4K 0.05% 246
2024
Q2
$638K Sell
9,293
-1,117
-11% -$74.5K 0.05% 278
2024
Q1
$763K Sell
10,410
-2,048
-16% -$157K 0.06% 238
2023
Q4
$1.01M Buy
12,458
+450
+4% +$35K 0.08% 190
2023
Q3
$900K Sell
12,008
-717
-6% -$55.1K 0.08% 187
2023
Q2
$981K Buy
12,725
+76
+0.6% +$6.06K 0.09% 193
2023
Q1
$1.05M Buy
12,649
+78
+0.6% +$6.46K 0.1% 178
2022
Q4
$1.08M Buy
12,571
+143
+1% +$11.3K 0.11% 163
2022
Q3
$767K Buy
12,428
+999
+9% +$63K 0.09% 206
2022
Q2
$706K Buy
11,429
+2,157
+23% +$134K 0.08% 219
2022
Q1
$566K Sell
9,272
-2,300
-20% -$147K 0.05% 287
2021
Q4
$844K Buy
11,572
+488
+4% +$33.6K 0.08% 222
2021
Q3
$774K Sell
11,084
-1,277
-10% -$89.7K 0.07% 232
2021
Q2
$852K Buy
12,361
+423
+4% +$28.2K 0.08% 210
2021
Q1
$785K Sell
11,938
-503
-4% -$32.4K 0.08% 208
2020
Q4
$725K Sell
12,441
-11,375
-48% -$686K 0.08% 201
2020
Q3
$1.5M Buy
23,816
+10,227
+75% +$709K 0.19% 97
2020
Q2
$1.05M Buy
13,589
+887
+7% +$68K 0.14% 126
2020
Q1
$950K Buy
+12,702
New +$878K 0.16% 115
2019
Q3
$737K Sell
11,624
-152
-1% -$9.94K 0.09% 120
2019
Q2
$796K Sell
11,776
-130
-1% -$8.55K 0.1% 168
2019
Q1
$774K Buy
11,906
+203
+2% +$13.5K 0.1% 162
2018
Q4
$732K Sell
11,703
-1,570
-12% -$110K 0.11% 97
2018
Q3
$1.02M Sell
13,273
-651
-5% -$49.2K 0.14% 123
2018
Q2
$986K Sell
13,924
-9,028
-39% -$638K 0.14% 119
2018
Q1
$1.73M Sell
22,952
-723
-3% -$57.5K 0.27% 68
2017
Q4
$1.7M Sell
23,675
-750
-3% -$57K 0.29% 69
2017
Q3
$1.98M Buy
24,425
+982
+4% +$75.1K 0.36% 60
2017
Q2
$1.66M Sell
23,443
-836
-3% -$55.6K 0.32% 66
2017
Q1
$1.65M Buy
24,279
+4,423
+22% +$311K 0.28% 73
2016
Q4
$1.42M Buy
19,856
+4,874
+33% +$362K 0.26% 77
2016
Q3
$1.19M Sell
14,982
-3,983
-21% -$324K 0.23% 91
2016
Q2
$1.58M Sell
18,965
-1,194
-6% -$106K 0.3% 69
2016
Q1
$1.85M Buy
20,159
+798
+4% +$72K 0.36% 58
2015
Q4
$1.96M Sell
19,361
-2,032
-9% -$211K 0.41% 47
2015
Q3
$2.1M Buy
21,393
+1,473
+7% +$164K 0.48% 47
2015
Q2
$2.33M Buy
19,920
+2,448
+14% +$267K 0.53% 41
2015
Q1
$1.72M Buy
17,472
+838
+5% +$85.1K 0.39% 54
2014
Q4
$1.57M Sell
16,634
-770
-4% -$79.6K 0.36% 58
2014
Q3
$1.85M Buy
17,404
+899
+5% +$88K 0.44% 48
2014
Q2
$1.37M Buy
16,505
+922
+6% +$71.8K 0.33% 67
2014
Q1
$1.1M Buy
15,583
+1,996
+15% +$157K 0.3% 67
2013
Q4
$1.02M Sell
13,587
-343
-2% -$23.9K 0.31% 71
2013
Q3
$876K Sell
13,930
-162
-1% -$9.68K 0.28% 72
2013
Q2
$722K Buy
+14,092
New +$735K 0.25% 78

Other funds holding GILD

Rehmann Capital Advisory Group's GILD Position: Q2 2026 in Review

Rehmann Capital Advisory Group increased its Gilead Sciences (GILD) stake by 0.5% in Q2 2026, buying an estimated $7.64K and bringing the position to 11,708 shares worth $1.48M. The position accounts for 0.07% of the portfolio, ranked #202.

Rehmann Capital Advisory Group first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.33M in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Rehmann Capital Advisory Group held 11,708 shares of Gilead Sciences worth $1.48M as of Q2 2026.
  • Rehmann Capital Advisory Group bought 58 Gilead Sciences shares in Q2 2026, an estimated $7.64K.
  • Gilead Sciences made up 0.07% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #202 holding.
  • Rehmann Capital Advisory Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • Rehmann Capital Advisory Group's Gilead Sciences position peaked at $2.33M in Q2 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.